Billets de Michelle Dawson

Billet publié sur Twitter/X le 29/12/2022 17:05

Retour aux billets Billet précédent Billet suivant
Twitter/X Essai clinique clinicaltrials.gov Extrait cité dans le billet Question posée par Dawson dans le billet Lien intégré au billet Termes sur l’autisme
Ouvrir le billet original

Infos sur le lien intégré au billet

Essai clinique

Stanford University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2023). Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial. ClinicalTrials.gov. Stanford University.

Plus d’infos

Liens cités structurés

1 ressource citée

Essai clinique Récupéré Publication clinicaltrials.gov

Stanford University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2023). Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial. ClinicalTrials.gov. Stanford University.

Date de publication
26/04/2023
Identifiant
NCT05664789
Auteurs
Stanford University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Source
ClinicalTrials.gov
Type de référence
clinical_trial
Éditeur
Stanford University
Source de métadonnées
clinicaltrials.gov

Résumé

The goal of this study is to target the neurobiology of restricted and repetitive behaviors in children with autism spectrum disorder using N-acetylcysteine (NAC), a well-tolerated nutritional supplement that has shown promise for reducing symptom severity in recent small-scale trials. The findings from this research will shed light on the mechanisms of action underlying the clinical benefits of NAC and the effects of NAC on altering restricted and repetitive behavior symptom severity in children with autism spectrum disorder. This is a 12-week double-blind, randomized, placebo-controlled trial of NAC.

Ouvrir la source Lien vers la source citée